New Transcreener UDP2 Assay with a Fluorescence Intensity Readout

Transcreener Glycosyltransferase Assay Blog
BellBrook Labs scientists have developed a new universal UDP detection assay for the measurement of Glycosyltransferase activity.  The Transcreener UDP2 FI Assay extends the Transcreener platform for UDP detection by utilizing a simple fluorescence intensity (FI) output. It can be used on fluorescence readers typically found in academic and therapeutic research laboratories, as well as
Read more
No Comments

New Transcreener CD73 Assay for Discovery of Therapeutics to Enhance Tumor Immunity

cGAS Inhibitors Grant
The new Transcreener CD73 Assay measures adenosine production by CD73 in a mix-and-read format with a far-red fluorescence polarization readout. The assay will accelerate efforts to discover selective CD73 antagonists for cancer immunotherapy by enabling high throughput screening, structure-driven hit-to-lead, and mechanistic studies with the purified enzyme. Madison, WI – April 27th, 2020 – Researchers
Read more
No Comments

Recorded Webinar – Transcreener® CD73 Assay: Leveraging Nucleotide Detection to Measure Adenosine

Webinar Graphic
CD73 is a plasma membrane-bound ectonucleotidase that hydrolyzes AMP into adenosine, contributing to immunosuppression in the tumor microenvironment; it is being pursued as a promising immuno-oncology drug target. In this webinar we will present the steps involved in development of the Transcreener CD73 assay. Transcreener is a biochemical HTS assay platform based on homogenous immunodetection
Read more
No Comments

SLAS 2020 – Discover HTS Assays for Drug Discovery

SLAS 2020 Conference
  BellBrook Labs will exhibit and present posters at the upcoming SLAS 2020 conference in San Diego, CA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting ENPP1, studying CD73, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
Read more
No Comments

BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery

New Transcreener cGAS Assay
The new Transcreener cGAMP cGAS Assay directly measures the product cGAMP, in a cGAS enzymatic reaction allowing researchers to screen vast compound libraries for novel modulators. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by targeting the cGAS-STING pathway. Madison, WI – Researchers at BellBrook Labs have
Read more
No Comments

Discovery On Target 2019 – Let’s Talk Drug Discovery

Discovery On Target 2019
  BellBrook Labs will exhibit and present posters at the upcoming Discovery On Target conference in Boston, MA. At the event BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, studying CD73 and CD39, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
Read more
No Comments

BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases

cGAS Inhibitors Grant
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway. Madison, WI – July 2019
Read more
No Comments

Researchers from BellBrook Labs Pen Chapter in Springer’s Rho GTPases: Methods and Protocols

Rho GTPases Rho GEFs Book
New Protocol from BellBrook Labs: High-Throughput Assay for Rho GEFs Based on the Transcreener GDP Assay In this new second edition of Springer Nature’s Rho GTPases: Methods and Protocols, researchers from BellBrook Labs describe an HTS compatible method for detecting GTPase exchange factor (GEF) activity. The protocol described in chapter twelve of the book uses
Read more
No Comments

Visit With BellBrook Labs at Discovery On Target 2018

Discovery on Target 2018
BellBrook Labs will exhibit and present posters at the upcoming Discovery on Target conference in Boston, MA. At the event BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, methyltransferase activity measurement, studying ectonucleotidase enzymes, screening for kinase inhibitors, and more! Discovery on Target 2018 Sheraton Boston Hotel
Read more
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Read more
No Comments